{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:49:55Z","timestamp":1786988995334,"version":"build-2736575974"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.euo.2023.10.021","type":"journal-article","created":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T16:17:17Z","timestamp":1699114637000},"page":"319-322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Evaluation of a miRNA-371a-3p Assay for Predicting Final Histopathology in Patients Undergoing Primary Nerve-sparing Retroperitoneal Lymphadenectomy for Stage IIA\/B Seminoma or Nonseminoma"],"prefix":"10.1016","volume":"7","author":[{"given":"Felix","family":"Seelemeyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Pappesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Merkelbach-Bruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Paffenholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2511-3664","authenticated-orcid":false,"given":"Axel","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2023.10.021_b0005","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.mcna.2017.10.003","article-title":"Testicular cancer: epidemiology, diagnosis, and management","volume":"102","author":"Smith","year":"2018","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.euo.2023.10.021_b0010","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.eururo.2023.04.010","article-title":"European Association of Urology guidelines on testicular cancer: 2023 update","volume":"84","author":"Patrikidou","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2023.10.021_b0015","unstructured":"American Urological Association. Testicular cancer guidelines. American Urological Association Web site. http:\/\/www.auanet.org\/guidelines-and-quality\/guidelines\/oncology-guidelines\/testicular-cancer."},{"key":"10.1016\/j.euo.2023.10.021_b0020","doi-asserted-by":"crossref","unstructured":"Heidenreich A, Paffenholz P, Hartmann F, Seelemeyer F, Pfister D. Retroperitoneal lymph node dissection in clinical stage IIA\/N metastatic seminoma. Results of the Cologne trial of retroperitoneal lymphadenectomy in metastatic seminoma (COTRIMS). Eur Urol 2024;7(1):122\u2013127.","DOI":"10.1016\/j.euo.2023.06.004"},{"key":"10.1016\/j.euo.2023.10.021_b0025","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.eururo.2022.10.021","article-title":"Phase 2 single-arm trial of primary retroperitoneal lymph node dissection in patients with seminomatous testicular germ cell tumors with clinical stage IIA\/B (PRIMETEST)","volume":"84","author":"Hiester","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2023.10.021_b0030","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1200\/JCO.22.00624","article-title":"Surgery in early metastatic seminoma: a phase II trial of retroperitoneal lymph node dissection for testicular seminoma with limited retroperitoneal lymphadenopathy","volume":"41","author":"Daneshmand","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2023.10.021_b0035","doi-asserted-by":"crossref","first-page":"687.e13","DOI":"10.1016\/j.urolonc.2020.03.014","article-title":"National management trends in clinical stage IIA nonseminomatous germ cell tumor (NSGCT) and opportunities to avoid dual therapy","volume":"38","author":"Labbate","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2023.10.021_b0040","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.3390\/cancers14051190","article-title":"Diverse roles and targets of miRNA in the pathogenesis of testicular germ cell tumour","volume":"14","author":"Das","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.euo.2023.10.021_b0045","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.18.01480","article-title":"Serum levels of microRNA-371a-3p (M371 test) as a new biomarker of testicular germ cell tumors: results of a prospective multicentric study","volume":"37","author":"Dieckmann","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2023.10.021_b0050","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00432-020-03429-x","article-title":"Serum levels of microRNA-371a-3p are not elevated in testicular tumours of non-germ cell origin","volume":"147","author":"Belge","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.euo.2023.10.021_b0055","doi-asserted-by":"crossref","first-page":"15582","DOI":"10.1038\/s41598-021-94812-2","article-title":"Serum miR371 in testicular germ cell cancer before and after orchiectomy, assessed by digital-droplet PCR in a prospective study","volume":"11","author":"Myklebust","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.euo.2023.10.021_b0060","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1200\/JCO.18.02057","article-title":"Developing a highly specific biomarker for germ cell malignancies: plasma miR371 expression across the germ cell malignancy spectrum","volume":"37","author":"Nappi","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2023.10.021_b0065","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/andr.13317","article-title":"Evaluation of miR371a-39 to predict viable germ cell tumor in patients with pure seminoma receiving retroperitoneal lymph node dissection","volume":"11","author":"Konneh","year":"2023","journal-title":"Andrology"},{"key":"10.1016\/j.euo.2023.10.021_b0070","doi-asserted-by":"crossref","first-page":"10558","DOI":"10.1038\/s41598-023-37271-1","article-title":"Refining the serum miR-371a-3p test for viable germ cell tumor detection","volume":"13","author":"Lafin","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.euo.2023.10.021_b0075","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.eururo.2019.10.005","article-title":"Serum microRNA-371a-3p levels predict viable germ cell tumor in chemotherapy-na\u00efve patients undergoing retroperitoneal lymph node dissection","volume":"77","author":"Lafin","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2023.10.021_b0080","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1200\/JCO.2007.12.0899","volume":"26","author":"Albers","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2023.10.021_b0085","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/cncr.34571","article-title":"Differentially expressed messenger RNA\/proteins can distinguish teratoma from necrosis in postchemotherapy retroperitoneal lymph node dissection tissue","volume":"129","author":"Nestler","year":"2023","journal-title":"Cancer"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931123002365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931123002365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T21:24:38Z","timestamp":1715808278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931123002365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2588931123002365"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2023.10.021","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of a miRNA-371a-3p Assay for Predicting Final Histopathology in Patients Undergoing Primary Nerve-sparing Retroperitoneal Lymphadenectomy for Stage IIA\/B Seminoma or Nonseminoma","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2023.10.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}